Verastem, Inc. (VSTM)

NCM – Real vaqt narxi. Valyuta: USD

6.95

-0.10 (-1.42%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

6.92

-0.03 (-0.43%)

Bozordan keyin: Aug 12, 2026, 6:16 PM EDT

07.08.2026

Verastem Q2 Earnings Call Highlights

Verastem NASDAQ: VSTM reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in commercial performance.

07.08.2026

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

06.08.2026

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem (VSTM) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $0.39 per share a year ago.

06.08.2026

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. “The second quarter marked meaningful progress across our commercial business and pipeline programs, with strong quarter-over-quarter growth for AVMAPKI FAKZYNJA CO-PACK driven by new patient starts and in.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Verastem, Inc. (VSTM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Verastem, Inc. (VSTM)

Verastem Q2 Earnings Call Highlights

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Videolar

No Data

Press-relizlar

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Q2 Earnings Call Highlights

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Videolar

No Data

Press-relizlar

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Search stocks

Verastem, Inc. (VSTM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Verastem, Inc. (VSTM)

Verastem Q2 Earnings Call Highlights

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Videolar

No Data

Press-relizlar

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Q2 Earnings Call Highlights

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Videolar

No Data

Press-relizlar

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates